Thursday, June 08, 2023 8:20:04 PM
ATLnsider,
One thing I forgot to mention is that if the makers of those other combo drugs go along with the kind of trial design you suggest, which makes sense on the surface based on L trial results, the data created might effectively put them out of business if what I believe is going to happen occurs. Would they risk that without trying to own NWBO first at almost any cost?; ). See why there might be folks trying to keep the price down while also creating the low price buyout narrative by utilizing so many potential “helpers”?; ).
The gradual shift in focus on this board to share price seems geared towards longs who want to come up for air. Linda knows this and is working very hard to create great value before any interim news is announced that might get longs to sell in the low range targets being bandied around here. Better for me to pass the shares on to the next gen and others than sell low to manipulators. Best wishes.
One thing I forgot to mention is that if the makers of those other combo drugs go along with the kind of trial design you suggest, which makes sense on the surface based on L trial results, the data created might effectively put them out of business if what I believe is going to happen occurs. Would they risk that without trying to own NWBO first at almost any cost?; ). See why there might be folks trying to keep the price down while also creating the low price buyout narrative by utilizing so many potential “helpers”?; ).
The gradual shift in focus on this board to share price seems geared towards longs who want to come up for air. Linda knows this and is working very hard to create great value before any interim news is announced that might get longs to sell in the low range targets being bandied around here. Better for me to pass the shares on to the next gen and others than sell low to manipulators. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
